Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Michael T. Andriole, President and CEO of Chimerix Inc . (NASDAQ:CMRX), recently sold 7,370 shares of the company's common stock, according to a recent SEC filing. The shares were sold at a weighted ...

(RTTNews) - Shares of Chimerix (CMRX) touched a new high of $5.15 yesterday, with the company moving one step closer to its goal of accelerating access to the first medicine specific to patients ...

Equities research analysts at Wedbush boosted their FY2028 earnings per share estimates for shares of Chimerix in a research note issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They ...

Chimerix ...

DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement ...

Investing.com -- Chimerix（纳斯达克股票代码：CMRX）股价上涨12.5%，此前该公司宣布美国食品和药物管理局（FDA）已接受其新药申请（NDA），用于治疗复发性H3 ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure ...